 Survival Rate
"Survival Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
| Descriptor ID |
D015996
|
| MeSH Number(s) |
E05.318.308.985.550.900 L01.280.975.550.900 N01.224.935.698.826 N06.850.505.400.975.550.900 N06.850.520.308.985.550.900
|
| Concept/Terms |
Survival Rate- Survival Rate
- Rate, Survival
- Rates, Survival
- Survival Rates
Mean Survival Time- Mean Survival Time
- Mean Survival Times
- Survival Time, Mean
- Survival Times, Mean
- Time, Mean Survival
- Times, Mean Survival
Cumulative Survival Rate- Cumulative Survival Rate
- Cumulative Survival Rates
- Rate, Cumulative Survival
- Rates, Cumulative Survival
- Survival Rate, Cumulative
- Survival Rates, Cumulative
|
Below are MeSH descriptors whose meaning is more general than "Survival Rate".
Below are MeSH descriptors whose meaning is more specific than "Survival Rate".
This graph shows the total number of publications written about "Survival Rate" by people in this website by year, and whether "Survival Rate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1988 | 0 | 1 | 1 | | 1989 | 0 | 4 | 4 | | 1990 | 0 | 13 | 13 | | 1991 | 0 | 17 | 17 | | 1992 | 0 | 12 | 12 | | 1993 | 0 | 14 | 14 | | 1994 | 0 | 36 | 36 | | 1995 | 0 | 40 | 40 | | 1996 | 0 | 24 | 24 | | 1997 | 0 | 33 | 33 | | 1998 | 0 | 45 | 45 | | 1999 | 0 | 30 | 30 | | 2000 | 0 | 38 | 38 | | 2001 | 0 | 32 | 32 | | 2002 | 0 | 31 | 31 | | 2003 | 1 | 35 | 36 | | 2004 | 0 | 32 | 32 | | 2005 | 0 | 31 | 31 | | 2006 | 0 | 37 | 37 | | 2007 | 0 | 28 | 28 | | 2008 | 0 | 56 | 56 | | 2009 | 0 | 47 | 47 | | 2010 | 0 | 77 | 77 | | 2011 | 0 | 82 | 82 | | 2012 | 0 | 60 | 60 | | 2013 | 1 | 65 | 66 | | 2014 | 0 | 68 | 68 | | 2015 | 0 | 62 | 62 | | 2016 | 0 | 61 | 61 | | 2017 | 0 | 63 | 63 | | 2018 | 0 | 43 | 43 | | 2019 | 0 | 82 | 82 | | 2020 | 0 | 44 | 44 | | 2021 | 0 | 14 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Survival Rate" by people in Profiles.
-
Squires MH, Ethun CG, Donahue EE, Benbow JH, Anderson CJ, Jagosky MH, Salo JC, Hill JS, Ahrens W, Prabhu RS, Livingston MB, Gower NL, Needham M, Trufan SJ, Fields RC, Krasnick BA, Bedi M, Abbott DE, Schwartz P, Votanopoulos K, Chouliaras K, Grignol V, Roggin KK, Tseng J, Poultsides G, Tran TB, Cardona K, Howard JH. A multi-institutional validation study of prognostic nomograms for retroperitoneal sarcoma. J Surg Oncol. 2021 Oct; 124(5):829-837.
-
Karagodin I, Carvalho Singulane C, Woodward GM, Xie M, Tucay ES, Tude Rodrigues AC, Vasquez-Ortiz ZY, Alizadehasl A, Monaghan MJ, Ordonez Salazar BA, Soulat-Dufour L, Mostafavi A, Moreo A, Citro R, Narang A, Wu C, Descamps T, Addetia K, Lang RM, Asch FM. Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study. J Am Soc Echocardiogr. 2021 08; 34(8):819-830.
-
Chen B, Lu C, Gu HQ, Li Y, Zhang G, Lio J, Luo X, Zhang L, Hu Y, Lan X, Chen Z, Xie Q, Pan H. Serum Uric Acid Concentrations and Risk of Adverse Outcomes in Patients With COVID-19. Front Endocrinol (Lausanne). 2021; 12:633767.
-
Scott LC, Bartley S, Dowling NF, Richardson LC. Finding "Bright Spots": Using Multiple Measures to Examine Local-Area Racial Equity in Cancer Mortality Outcomes. Am J Epidemiol. 2021 04 06; 190(4):673-680.
-
Chau B, Ituarte PH, Shinde A, Li R, Vazquez J, Glaser S, Massarelli E, Salgia R, Erhunmwunsee L, Ashing K, Amini A. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med. 2021 04; 10(8):2660-2667.
-
Larson RA, Mandrekar SJ, Huebner LJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Döhner H, Stone RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
-
Prischl FC, Rossing P, Bakris G, Mayer G, Wanner C. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497.
-
Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia. 2021 08; 35(8):2220-2231.
-
Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 01 26; 5(2):504-512.
-
Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, Motley LS, Teachey DT, Wertheim GB, Wray L, DiNofia AM, Grupp SA. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 03 10; 39(8):920-930.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|